Overall, our data are consistent with previous reports associating low IGF-1 bioactivity with longer overall, disease-free and event-free survival in NSCLC (Chang et al, 2002; Han et al, 2006). This evidence concerns the gene IGF1 and non-small cell lung carcinoma.